XVIVO Perfusion is launching its newly developed appliance for lung perfusion,
XPS™ (Xvivo Perfusion System), in Europe on the basis of good clinical results
and great interest from clinics.
Since 2009, XVIVO Perfusion AB (publ) has developed and sought patents for a
complete system for the evaluation of lungs (EVLP) so as to facilitate use of
STEEN Solution™. XPS™ also contains a ventilator and will be marketed with
accompanying specially adapted disposable products. By increasing the number of
lungs available for transplantation, more patients with severe lung disease can
be given a longer and better quality of life.
XPS™ has been developed in contact with Toronto General Hospital and according
to their successful clinical development of EVLP. It has now been successfully
used for two years at leading transplant centers in the USA within the framework
of the NOVEL study. EVLP together with STEEN Solution™ following the Toronto
protocol has already been used in more than 80 lung transplantations at many
leading centers in Europe and more than 200 transplants worldwide, saving lungs
that otherwise would not have been used. The XPS™ will make the EVLP procedure
easier to perform, demand less time to set up and use fewer personnel than would
a manually performed EVLP.
XPS™ is based on innovative technology from leading companies such as Maquet
(Getinge) and Hamilton Medical and it is planned to receive a CE mark during the
first quarter of 2014 together with the accompanying disposable products.
“So far we have held back on a decision to launch the XPS™ in Europe, but
bearing in mind the very good clinical results and the great interest that we
have noted from clinics in Europe, we are now working on a market introduction
in Europe,” says XVIVO Perfusion’s CEO, Dr. Magnus Nilsson.
October 18, 2013
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, tel: +46 31 788 21 59, e-mail:
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com
Xvivo Perfusion is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication
on October 18, 2013 at 10:30 a.m.
This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: email@example.com. Website: www.xvivoperfusion.com
GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.